Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00362089
Other study ID # EKFZ001_CN
Secondary ID INFAT
Status Completed
Phase N/A
First received August 8, 2006
Last updated February 3, 2014
Start date June 2006
Est. completion date November 2010

Study information

Verified date February 2014
Source Technische Universität München
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics Commission
Study type Interventional

Clinical Trial Summary

Pregnant and lactating women receive n-3 fatty acids starting from week 15 of gestation until 4 months post-partum (pp) in comparison to a control group, who only gets information about adequately healthy nutrition during pregnancy and lactation.

The amount of fat in newborns is measured through skinfold thickness, ultrasound, and magnetic resonance imaging (MRI).

It is hypothesised that a reduction in arachidonic acid intake and an increase of n-3 LC PUFAs (long chain polyunsaturated fatty acids) via supplements containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) could lead to less expansive fat tissue development in the first year of life.


Description:

The prevalence of overweight and obese children and adolescents dramatically increased during the last two decades. In Germany every 5th school child is overweight and 4 - 8% of all children are obese.

Recent studies suggest that fatty acids in maternal nutrition may have an impact on the fat tissue development during the fetal period.

Animal studies showed that a reduction in the arachidonic acid intake, a higher intake of n-3 LC PUFAs (i.e. DHA and EPA) and a resulting lower n-6/n-3 fatty acid ratio in food will cause less expansive fat tissue development in the first year of life.

In vitro studies and personal observations in animal studies also showed that n-6 fatty acids (i.e. arachidonic acid) stimulate the differentiation of preadipocytes to adipocytes whereas n-3 fatty acids (i.e. DHA and EPA) have the contrary effect.

The impact of the maternal fatty acid pattern on the early fat tissue development can only be clarified in an intervention study.

Therefore it is planned to recruit 204 pregnant women in the 14th week of gestation. They will be randomly assigned to the intervention or control group.

The intervention group will receive n-3 LC-PUFAs (DHA and EPA) as fish oil capsules from the 15th week of gestation until 4 months pp, the control group will get nutrition counselling according to the recommendations of the German Society for Nutrition during the same time period. Blood samples of the pregnant and lactating women, umbilical cord blood, placental tissue and blood of the newborns will be collected for fatty acid analysis.

Body fat mass in newborns will be determined from delivery until 4 months pp via skinfold measurement, ultrasound, and MRI.

The hypothesis is that newborns in the group of the "supplemented" mothers will have less expansive fat tissue development than children from mothers in the control group.

This would be an innovative primary preventive approach in a period of increasing prevalence of overweight and obese children and adolescents.


Recruitment information / eligibility

Status Completed
Enrollment 208
Est. completion date November 2010
Est. primary completion date November 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 43 Years
Eligibility Inclusion Criteria:

- Gestational age <= 15th week of gestation

- Age: 18-43 years

- Written informed consent

- Body mass index (BMI) before pregnancy between 18 and 30 km/m2

Exclusion Criteria:

- High risk pregnancy

- Hypertonus

- Chronic diseases (i.e. diabetes mellitus)

- Psychiatric diseases

- Former supplementation with LC-PUFA

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Marinol D-40
Marinol D-40, three capsules per day, from 15th week of gestation until 4th month of lactation

Locations

Country Name City State
Germany Else Kröner-Fresenius-Zentrum für Ernährungsmedizin, Technische Universität München Munich

Sponsors (3)

Lead Sponsor Collaborator
Technische Universität München Else Kröner-Fresenius-Foundation; International Unilever-Foundation; Danone Research, EU funding by EARNEST consortium;German Ministry of Education and Research GF-GFGI01120708)

Country where clinical trial is conducted

Germany, 

References & Publications (6)

Brunner S, Schmid D, Hüttinger K, Much D, Brüderl M, Sedlmeier EM, Kratzsch J, Amann-Gassnerl U, Bader BL, Hauner H. Effect of reducing the n-6/n-3 fatty acid ratio on the maternal and fetal leptin axis in relation to infant body composition. Obesity (Silver Spring). 2014 Jan;22(1):217-24. doi: 10.1002/oby.20481. Epub 2013 Sep 10. — View Citation

Brunner S, Schmid D, Hüttinger K, Much D, Heimberg E, Sedlmeier EM, Brüderl M, Kratzsch J, Bader BL, Amann-Gassner U, Hauner H. Maternal insulin resistance, triglycerides and cord blood insulin in relation to post-natal weight trajectories and body composition in the offspring up to 2 years. Diabet Med. 2013 Dec;30(12):1500-7. doi: 10.1111/dme.12298. Epub 2013 Sep 11. — View Citation

Hauner H, Much D, Vollhardt C, Brunner S, Schmid D, Sedlmeier EM, Heimberg E, Schuster T, Zimmermann A, Schneider KT, Bader BL, Amann-Gassner U. Effect of reducing the n-6:n-3 long-chain PUFA ratio during pregnancy and lactation on infant adipose tissue g — View Citation

Hauner H, Vollhardt C, Schneider KT, Zimmermann A, Schuster T, Amann-Gassner U. The impact of nutritional fatty acids during pregnancy and lactation on early human adipose tissue development. Rationale and design of the INFAT study. Ann Nutr Metab. 2009;54(2):97-103. doi: 10.1159/000209267. Epub 2009 Mar 19. — View Citation

Much D, Brunner S, Vollhardt C, Schmid D, Sedlmeier EM, Brüderl M, Heimberg E, Bartke N, Boehm G, Bader BL, Amann-Gassner U, Hauner H. Breast milk fatty acid profile in relation to infant growth and body composition: results from the INFAT study. Pediatr Res. 2013 Aug;74(2):230-7. doi: 10.1038/pr.2013.82. Epub 2013 May 28. — View Citation

Much D, Brunner S, Vollhardt C, Schmid D, Sedlmeier EM, Brüderl M, Heimberg E, Bartke N, Boehm G, Bader BL, Amann-Gassner U, Hauner H. Effect of dietary intervention to reduce the n-6/n-3 fatty acid ratio on maternal and fetal fatty acid profile and its relation to offspring growth and body composition at 1 year of age. Eur J Clin Nutr. 2013 Mar;67(3):282-8. doi: 10.1038/ejcn.2013.2. Epub 2013 Jan 23. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary amount of fat mass in the offspring skinfold thickness measurements at birth, 6 weeks, 4 months, 1 year postpartum No
Secondary amount of fat mass in the offspring skinfold thickness measurements at 1,5 years, 2 years, 2.5 years, 3 years, 4 years and 5 years postpartum (follow-up) No
Secondary offspring body height at birth, 6 weeks, 4 months, 1 year, 1.5 years, 2 years, 2.5 years, 3 years, 4 years and 5 years postpartum No
Secondary head circumference of newborns, infants and children at birth, 6 weeks, 4 months, 1 year, 1.5 years, 2 years, 2.5 years, 3 years, 4 years and 5 years postpartum No
Secondary blood lipids of pregnant and lactating women 15th wk gestation, 32nd wk gestation, 6 weeks pp, 4 months pp No
Secondary fatty acid profile of phospholipids and erythrocyte membrane lipids, fatty acid metabolites maternal and offspring blood cells and plasma, placenta, umbilical cord tissue, blood cells and plasma, breast milk 15th wk gestation, 32nd wk gestation, birth, 6 wks, 4 months, 1 year, 3 years postpartum No
Secondary daily intake of maternal fatty acids 7 day dietary records 15 wks gestation, 32nd wks gestation, 6 wks pp No
Secondary offspring abdominal subcutaneous and preperitoneal fat Ultrasonography 6 weeks, 4 months , 1 year , 1.5 years , 2 years, 2.5 years, 3 years, 4 years, 5 years postpartum No
Secondary offspring fat mass, abdominal fat magnetic resonance imaging 6 weeks, 4 months, 5 years postpartum No
Secondary maternal and offspring gene expression (mRNA, miRNA) placenta, umbilical cord tissue, white blood cells, blood plasma 15 wk gestation, 32nd wk gestation (maternal), birth, 3 years (offspring) No
Secondary maternal and offspring DNA analysis (SNPs, DNA methylation) placenta, umbilical cord tissue, white blood cells 15 wk gestation, 32nd wk gestation (maternal), birth, 3 years (offspring) No
Secondary epigenetic analyses (histone modification, DNA methylation) placenta, umbilical cord tissue, white blood cells birth No
Secondary cytokines, adipokines and hormone analysis maternal and offspring blood cells and plasma, placenta, umbilical cord blood cells and plasma, breast milk 15th wk gestation, 32nd wk gestation, 6 wks pp, 4 months pp (maternal), birth, 4 months, 1 year, 3 years postpartum (offspring) No
Secondary protein analysis, proteomics maternal and offspring blood cells and plasma, placenta, umbilical cord blood cells and plasma 15th wk gestation, 32nd wk gestation (maternal), birth, 4 months, 1 year, 3 years postpartum (offspring) No
Secondary metabolomics, lipidomics maternal and offspring blood cells and plasma, placenta, umbilical cord blood cells and plasma 15th wk gestation, 32nd wk gestation (maternal), birth, 4 months, 1 year, 3 years postpartum (offspring) No
Secondary breast milk oligosaccharides 6 wks and 4 months postpartum No
Secondary offspring atopic eczema parent questionnaire 1.5 years - 5 years postpartum No
Secondary offspring allergic diseases (asthma, rhinitis) parent questionnaire 5 years postpartum No
Secondary developmental evaluation of children parent questionnaire (based on Minnesota Scales) 2 years - 5 years postpartum No
Secondary motor development of children 4 years and 5 years postpartum No
Secondary physical activity of children parent questionnaire 2 years - 5 years postpartum No
Secondary dietary intake of children 3 day dietary record 2 years - 5 years postpartum No
Secondary offspring body weight at birth, 6 weeks, 4 months, 1 year, 1.5 years, 2 years, 2.5 years, 3 years, 4 years and 5 years postpartum No
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2